MX2020000702A - Composiciones solidas orales de betahistina de liberacion prolongada no pulsatil. - Google Patents

Composiciones solidas orales de betahistina de liberacion prolongada no pulsatil.

Info

Publication number
MX2020000702A
MX2020000702A MX2020000702A MX2020000702A MX2020000702A MX 2020000702 A MX2020000702 A MX 2020000702A MX 2020000702 A MX2020000702 A MX 2020000702A MX 2020000702 A MX2020000702 A MX 2020000702A MX 2020000702 A MX2020000702 A MX 2020000702A
Authority
MX
Mexico
Prior art keywords
betahistine
dissolved
hours
weight
pulsatile
Prior art date
Application number
MX2020000702A
Other languages
English (en)
Inventor
Sunil Shantwan Borude
Himanshukumar Dasharathlal Patel
Vinod Purushottam Dube
Venkataramana Naidu
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59829185&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020000702(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of MX2020000702A publication Critical patent/MX2020000702A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a una composición sólida oral de liberación prolongada de 24 horas no pulsátil que comprende una cantidad de betahistina, o de una sal farmacéuticamente aceptable de esta, equivalente a 48 mg de diclorhidrato de betahistina, junto con uno o más excipientes o portadores farmacéuticamente aceptables, donde la composición presenta un perfil de disolución de acuerdo con el cual: se disuelve hasta un 30% en peso de betahistina en 1 hora; se disuelve de un 35% a un 45% en peso de betahistina en 2 horas; se disuelve de un 46% a un 60% en peso de betahistina en 4 horas; se disuelve de un 61% a un 80% en peso de betahistina en 8 horas; se disuelve de un 81% a un 97% en peso de betahistina en 16 horas; y se disuelve de un 98% a un 100% en peso de betahistina en 24 horas. También se refiere a su uso en terapia, particularmente en el tratamiento de una enfermedad o afección vestibular, más particularmente en el tratamiento de la enfermedad de Ménière.
MX2020000702A 2017-07-20 2018-07-16 Composiciones solidas orales de betahistina de liberacion prolongada no pulsatil. MX2020000702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721025857 2017-07-20
PCT/IB2018/055233 WO2019016668A1 (en) 2017-07-20 2018-07-16 NON-PULSATILE EXTENDED RELEASE BETAHISTINE ORAL SOLID COMPOSITIONS

Publications (1)

Publication Number Publication Date
MX2020000702A true MX2020000702A (es) 2020-10-14

Family

ID=59829185

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000702A MX2020000702A (es) 2017-07-20 2018-07-16 Composiciones solidas orales de betahistina de liberacion prolongada no pulsatil.

Country Status (22)

Country Link
US (1) US11433058B2 (es)
EP (2) EP3431078B1 (es)
JP (1) JP7084950B2 (es)
CN (1) CN110891551A (es)
AR (1) AR112281A1 (es)
AU (1) AU2018302771B2 (es)
BR (1) BR112020000977A2 (es)
CA (1) CA3069282A1 (es)
CL (1) CL2020000124A1 (es)
CO (1) CO2020001742A2 (es)
DK (1) DK3431078T3 (es)
ES (1) ES2862209T3 (es)
HR (1) HRP20210570T1 (es)
LT (1) LT3431078T (es)
MX (1) MX2020000702A (es)
PH (1) PH12020500001A1 (es)
PL (1) PL3431078T3 (es)
PT (1) PT3431078T (es)
SA (1) SA520411067B1 (es)
UY (1) UY37798A (es)
WO (1) WO2019016668A1 (es)
ZA (1) ZA202000030B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115266955B (zh) * 2021-04-29 2024-10-01 景忠山国药（唐山）有限公司 基于一测多评法的耳聋胶囊中成分含量的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1309591B1 (it) * 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
CN1551770A (zh) * 2001-07-06 2004-12-01 ������ҩ�����޹�˾ 羟吗啡酮控释制剂
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
EP1493435B1 (en) * 2003-07-04 2008-05-14 FARMACEUTICI FORMENTI S.p.A. Controlled Release Compositions of Betahistine
WO2012131722A1 (en) * 2011-03-30 2012-10-04 Sun Pharma Advanced Research Company Ltd. Controlled release composition of betahistine
DE102012105528A1 (de) 2012-06-25 2014-01-02 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur Freisetzung von Wirkstoffen
WO2014174073A1 (en) * 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib

Also Published As

Publication number Publication date
EP3431078B1 (en) 2021-01-20
CA3069282A1 (en) 2019-01-24
PT3431078T (pt) 2021-04-21
EP3431078A1 (en) 2019-01-23
US20210161871A1 (en) 2021-06-03
PL3431078T3 (pl) 2021-07-12
LT3431078T (lt) 2021-05-10
RU2020101925A3 (es) 2021-08-27
EP3654954A1 (en) 2020-05-27
CL2020000124A1 (es) 2020-09-21
HRP20210570T1 (hr) 2021-09-03
AU2018302771B2 (en) 2022-05-12
JP7084950B2 (ja) 2022-06-15
CO2020001742A2 (es) 2020-02-28
DK3431078T3 (da) 2021-04-19
CN110891551A (zh) 2020-03-17
WO2019016668A1 (en) 2019-01-24
AU2018302771A1 (en) 2020-01-16
RU2020101925A (ru) 2021-08-20
UY37798A (es) 2019-01-02
BR112020000977A2 (pt) 2020-07-14
JP2020528045A (ja) 2020-09-17
EP3654954A4 (en) 2021-06-16
AR112281A1 (es) 2019-10-09
SA520411067B1 (ar) 2022-09-28
ZA202000030B (en) 2021-08-25
US11433058B2 (en) 2022-09-06
PH12020500001A1 (en) 2020-09-14
ES2862209T3 (es) 2021-10-07

Similar Documents

Publication Publication Date Title
MX2019012884A (es) Terapia de combinacion.
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
ME02414B (me) Tretman kronove bolesti lakvinimodom
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2021002321A (es) Nuevos metodos.
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
MX2021002322A (es) Nuevos metodos.
ATE536172T1 (de) Ezetimibzusammensetzungen
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
WO2016011297A3 (en) Methods and related compositions for improved drug bioavailability and disease treatment
SA520411067B1 (ar) تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.